Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical innovator developing sustained-release therapies for retinal diseases and ocular conditions. This page serves as the definitive source for company news, providing investors and professionals with timely updates on clinical advancements, regulatory developments, and corporate milestones.
Access press releases, earnings reports, and analysis of key events impacting OCUL's trajectory. Our curated collection includes updates on AXPAXLI™ clinical trials for wet AMD, DEXTENZA® commercial performance, and pipeline progress across glaucoma and diabetic retinopathy therapies. Discover how the company's proprietary hydrogel platform addresses treatment challenges in ophthalmology.
Bookmark this page for streamlined access to OCUL's latest FDA submissions, partnership announcements, and financial disclosures. Stay informed about developments influencing both near-term performance and long-term growth in ocular therapeutics.
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for two new employees, including Thomas J. Cella, appointed as Executive Director of Payer Access. The awards, granted on April 7, 2025, include:
For Mr. Cella:
- Non-statutory stock option to purchase 26,000 shares
- Restricted stock unit award for 8,500 shares
For the non-executive employee:
- Non-statutory stock option to purchase 23,500 shares
- Restricted stock unit award for 7,700 shares
The stock options have a $6.30 per share exercise price and a ten-year term, vesting over four years. The restricted stock units vest over three years in equal annual installments, beginning April 7, 2026. These awards were granted under Ocular's 2019 Inducement Stock Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on retina treatments, has announced its participation in two major investor conferences this April. The first event is the 24th Annual Needham Virtual Healthcare Conference, where Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will present on Monday, April 7, 2025, at 3:00 PM ET in a virtual format.
The second event is the Piper Sandler Spring Biopharma Symposium in Boston, MA, scheduled for Thursday, April 17, 2025, where the company will host one-on-one meetings with investors. Interested parties can access a live webcast of the Needham presentation through the Events and Presentations section of Ocular's Investor Relations webpage.
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, effective March 3, 2025, include:
- A non-statutory stock option to purchase 48,000 shares at market price
- A restricted stock unit (RSU) award for 15,500 shares
The stock option has a 10-year term with a 4-year vesting schedule: 25% vesting on March 3, 2026, and the remainder monthly over three years. The RSU award vests over three years in equal annual installments, starting March 3, 2026. Both awards require continued employment with Ocular through vesting dates.
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 and full year 2024 results, highlighting significant progress in their AXPAXLI registrational program for wet AMD treatment. The company announced FDA approval for re-dosing at Weeks 52 and 76 in the SOL-1 trial, with primary endpoint data expected in Q1 2026.
Key financial highlights include:
- Cash position of $392.1M as of December 31, 2024, funding operations into 2028
- Q4 2024 total revenue of $17.1M, up 15.4% year-over-year
- Full year 2024 revenue of $63.7M, a 9.0% increase from 2023
- Q4 2024 net loss of $(48.4M), or $(0.29) per share
The company reduced SOL-R trial size to 555 subjects from 825, potentially accelerating registration timelines. FDA feedback on AXPAXLI in NPDR and DME is expected in 1H 2025.
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on redefining the retina experience, has announced its participation in two major investor conferences in March 2025.
The company will first attend the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, where Executive Chairman, President and CEO Pravin U. Dugel, MD will participate in a fireside chat at 11:50 AM ET.
Following this, Ocular will join the Leerink Partners Global Healthcare Conference 2025 in Miami Beach on Monday, March 10, 2025, with another fireside chat scheduled for 10:00 AM ET, also featuring Dr. Dugel.
Investors can access live webcasts of both presentations through the Events and Presentations section on the Investor Relations page of the Ocular Therapeutix website.
Ocular Therapeutix (NASDAQ: OCUL) has announced it will host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss its fourth quarter and full year 2024 financial results and recent business developments. The company, which focuses on redefining the retina experience, will provide access to the event through both U.S. (1-877-407-9039) and International (1-201-689-8470) dial-in numbers. The webcast will be available live and archived on the company's Investor Relations page for at least 30 days following the presentation.
Ocular Therapeutix (NASDAQ: OCUL) has announced multiple presentations scheduled for the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The presentations will focus on their key product OTX-TKI, featuring three distinct sessions:
1. Dr. Carl J. Danzig will present on OTX-TKI's progression from Phase 1 to Phase 3, discussing the SOL-1 and SOL-R trials for neovascular AMD at 2:30 PM ET.
2. Dr. Mark R. Barakat will share Phase 1 results of the intravitreal axitinib implant (OTX-TKI) for treating non-proliferative diabetic retinopathy at 5:20 PM ET.
3. Dr. Justis P. Ehlers will present volumetric macular fluid analysis findings from the HELIOS Clinical Trial at 5:25 PM ET, examining the impact of a single axitinib intravitreal implant in diabetic retinopathy treatment.
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards granted to a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The awards, effective January 13, 2025, include:
1. A non-statutory stock option to purchase 95,600 shares at market price, vesting over four years with 25% vesting on January 13, 2026, and the remainder monthly over three years.
2. A restricted stock unit award for 31,375 shares, vesting in equal annual installments over three years, starting January 13, 2026.
Both awards are contingent on continued employment with Ocular through the vesting dates.
Ocular Therapeutix (NASDAQ: OCUL) reported significant progress in its AXPAXLI™ clinical trials for wet age-related macular degeneration (wet AMD) and plans for non-proliferative diabetic retinopathy (NPDR). The company has enrolled 311 subjects in SOL-R, its second registrational trial for wet AMD, while completing randomization for SOL-1, its first registrational trial, with topline data expected in Q4 2025.
The company's wet AMD program consists of two complementary studies: SOL-1, a superiority trial comparing single AXPAXLI injection to aflibercept, and SOL-R, a non-inferiority trial evaluating repeat AXPAXLI injections. Both trials are designed to support a potential New Drug Application.
Following positive results from the Phase 1 HELIOS trial for NPDR, where no patients developed vision-threatening complications after 48 weeks with a single AXPAXLI injection, Ocular plans to seek FDA feedback on clinical trial design in H1 2025.
Ocular Therapeutix (NASDAQ: OCUL) announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 5:15 PM PT in San Francisco. Pravin U. Dugel, MD, the company's Executive Chairman, President and CEO, will provide updates on several key areas including:
- The enrollment status of SOL-R, their second registrational trial of AXPAXLI™ for treating wet age-related macular degeneration (wet AMD)
- Future opportunities for AXPAXLI
- A general corporate overview and strategic outlook for 2025
The presentation will be accessible through the Events and Presentations section of the company's Investor Relations webpage.
